U.S. FDA Relief For Ranbaxy
  • Prabha Hedge
  • Mar 28 2014

March 28: Bloomberg reports that the U.S. FDA has disputed a study of generic heart drugs by Preston Mason. The regulator said generics from overseas are safe, as it did not find contaminants in samples obtained through retail pharmacies. The stock of Ranbaxy today took heart from that news and shot up by 4% in intraday trade. Priya Sheth shares a detailed report on the same.